This document discusses biomedical science and biotechnology, specifically medical biotechnology. It notes that medical biotechnology uses life science technologies like biomedical engineering, bioinformatics and biotechnology to interface between medical devices, materials, software and human health. It provides context on global investment and growth in biotechnology and medical technology industries. The document outlines India's efforts to develop biotechnology research and education centers with international collaboration. It summarizes the current state of biotechnology in India compared to global standards and provides recommendations from national biotechnology reports to strengthen medical biotechnology in India.

1. †gwW‡Kj ev‡qv‡UK‡bvjwR|
o
ev‡qv‡gwW‡Kj weÁvb(Biomedical Science), gvbe kix‡ii wPwKrmvq e¨eüZ ev‡qvwdwRK¨vj
(ev‡qvjwR, ‡Kwgwóª I wdwR·) Kvh©¨µ‡g mswkó †gwW‡Kj hš¿cvwZ, Bgcøv›U, wWfvBm I gvbe kix‡ii g‡a¨
B›Uvi‡dm (Interface) wnmv‡e KvR K‡i| Aci w`‡K ‘‡gwW‡Kj ev‡qv‡U‡bvjwR’ (Medical
Biotechnology), ev‡qv‡gwW‡Kj weÁv‡biB GKwU kvLv; hvnv wPwKrmvq Rxe-cÖhyw³ e¨env‡ii gva¨‡g
gvbe-†ivM wbY©q I gyw³i be-Aa¨v‡qi m~Pbv Kwiqv‡Q |
Rxe cÖhyw³ GKwU `ªæZ ea©bkxj I MwZgq LvZ| wØZxq wek¦hy‡×i ci G wk‡íi M‡elYv I Dbœq‡b cÖPzi
A‡_©i wewb‡qvM NwUqv‡Q| ¯^v¯’¨-†mev wk‡í Rxe cÖhyw³ e¨env‡ii gva¨‡g bZzb mgvavb Ly‡R cvB‡Z nvRvi
nvRvi bZzb bZzb †Kv¤úvwbi AvZœcÖKvk NwUqv‡Q| Rxe cÖhyw³‡Z GZ e¨vcK AvMÖ‡ni KviY nBj GB Lv‡Z
iwnqv‡Q bZzb D™¢ebvi AwgZ m¤¢vebv| D`vniY ¯^iæc, ¯^v¯’¨ †mevq G cÖhyw³ bZzb bZzb Jla I Jla-‡hŠM
D™¢ve‡bi Kv‡R jvMv‡bv nB‡Z‡Q| wek¦ evRv‡ii wbqvgK, hy³iv‡óªi wkí Lv‡Z 2010 mv‡j G Lv‡Z 150
wewjqb BDGm Wjvi ivR¯^ Avq nBqv‡Q ewjqv avibv Kiv nq|
eZ©gv‡b Rxe cÖhyw³‡Z †bZ…¯’vbxq †`k¸‡jv n‡jv h_vµ‡g Pxb, hy³ivóª, fviZ, A‡ówjqv Ges d«vÝ|
Gwkqvb †`k¸‡jv‡Z miKvwifv‡eB Rxe cÖhyw³ welqK M‡elYv‡K GwM‡q †bqvi cÖavb f’wgKv cvjb Kiv
nB‡Z‡Q| Bnvi KviY,Rxe cÖhyw³ M‡elbvq AeKvVv‡gv Lv‡Z cÖPzi wewb‡qv‡Mi cª‡qvRb nq Ges cÖv_wgK
ch©v‡q AvqI †Zgb nq bv|
ZvB Gme †`‡k G ai‡Yi cuywRi †hvMvb GKgvÎ miKv‡ii c‡ÿB †`qv m¤¢e| Z‡e `wÿb †Kvwiqv, fviZ,
ZvBIqvb I wmsMvcy‡i †emiKvix ch©v‡qI Rxe cÖhyw³ welqK kw³kvjx M‡elYvagx© cÖwZôv‡bi Avwef©ve
NwUqv‡Q| fvi‡Z Rxe cÖhyw³ wk‡í wewb‡qvM weMZ 5 eQ‡i wZb ¸Y cÖe„w× nBqv‡Q| †m †`‡ki 150 wU Rxe
cÖhyw³ wkí cªwZôv‡bi wnmve Abyhvqx 2009-10 mv‡j G Lv‡Z 3 wewjqb BDGm Wjvi ivR¯^ Avq nBqv‡Q;
hvnv weMZ eQ‡ii Zzjbvq 17% †ekx|
Wvt †gvnv¤§` bRiæj Bmjvg
wefvMxq cÖavb
ev‡qv‡gwW‡Kj GÛ †gwW‡Kj ev‡qv‡UK‡bvjwR wefvM
knx` †mvnivIqv`x© †gwW‡Kj K‡jR I nvmcvZvj|XvKv
AvšÍRv©wZK Ges evsjv‡`k: wPwKrmv Rxe cÖhyw³i eZ©gvb
Ae¯’v, `„k¨cU I m¤¢vebv t

2. Rxe cÖhyw³ Lv‡Z gvbem¤ú` Dbœq‡bi Rb¨ fviZ miKvi BD‡b‡¯‹vi mnvqZvq Rxe cÖhyw³ welqK AvÂwjK
M‡elYv, cÖwkÿY I wkÿv †K›`ª (fviZ miKv‡ii wWcvU©‡g›U Ae ev‡qv‡UK‡bvjwR dwi`vev‡` GKwU ¯^v¯’¨
ev‡qv‡UK weÁvb K¬v÷vi mn) ¯’vcb Kwiqv‡Q| Bnv Qvov KY©vU‡K 10 wewjqb Wjv‡ii mxW gvwbmn GKwU
ev‡qv-‡fÂvi BbwKD‡eUi I 10 wU ev‡qv‡UK wdwbwks ¯‹zj cÖwZôv Kiv nBqv‡Q (Rxe cÖhyw³ wel‡q †gavex
gvbe m¤ú‡`i GKwU cyj ˆZwi Kivi j‡ÿ¨)|
AvšÍRv©wZK `„k¨cU t
2010 mv‡ji Rxe cÖhyw³ wPwKrmv wkÿv I wk‡íi wek¦ cwiw¯’wZ mviYx-1-G †`Lv‡bv nj|
(m~Î t RvZxq Rxe cÖhyw³ †M‡RU I AvB‡bi Lmov - 2010,2013 )|
evsjv‡`‡k wPwKrmv Rxe cÖhyw³i eZ©gvb Ae¯’v I evsjv‡`‡k wPwKrmv Rxe cÖhyw³i m¤¢vebvt
Avgv‡`i cvk¦©eZ©x †`k mg~nmn eZ©gvb we‡k¦i DbœZ wPwKrmv Rxe cÖhyw³i AMÖMwZi Zzjbvh evsjv‡`‡ki
wPwKrmv Rxe cÖhyw³i Ae¯’v GLbI AsKz‡iB iwnqv‡Q| 2003 mv‡j mgvß Gd.G.I. Ges BD.Gb.wW.wc
A_©vq‡b cwiPvwjZ GKwU Rxe cÖhyw³ g~j¨vqb M‡elYvq †`Lv hvq †h, evsjv‡`‡ki Rxe cÖhyw³ welqK
KvR¸‡jv nBqv‡Q g~jZt K…wl Lv‡Z|
wPwKrmv Rxe cÖhyw³ wel‡q m¤úvw`Z D‡jøL‡hvM¨ Kv‡Ri g‡a¨ iwnqv‡Q D`ivgq M‡elYv †K›`ª /
AvB.wm.wW.wW.Avi.we / icddrb KZ…©K wm‡Mjv f¨vKwmb Drcv`b (D`ivgq M‡elYv †K›`ª cÖvq `yÕ`kK a‡i
wPwKrmv Rxe cÖhyw³ wel‡q KvR Kwi‡Z‡Q| mv¤úªwZK Kv‡j cÖwZôvbwU AbyRxe †_‡K f¨vKwmb ˆZix, wKU
Ges Drcv`‡bi w`‡K g‡bv‡hvM w`qv‡Q)|
 evRv‡ii aib hyy³ivó BD‡ivc Gwkqv c¨vwmwdK KvbvWv evsjv‡`k
 weµq I ivR¯^
(wewjqb BDGm Wjvi)
72 12 3 2 welq wfwËK †Kvb WvUv- bvB|
*
 evwl©K M‡elYv I Dbœqb
(wewjqb BDGm Wjvi)
19 5 0.3 0.6 D‡jøL Kivi gZ †Kvb wewb‡qvM bvB|
*
 ‡Kv¤úvwbi msL¨v >1,500 >1,600 >700 >470 Avjv`v †Kvb ‡Kv¤úvwb bvB|
 gv‡K©U K¨vwcUvj
(wewjqb BDGm Wjvi)
491 26 15 14 Avjv`v †Kvb wnmve bvB|
*
 miKvix ‡Kv¤úvwbi msL¨v 363 120 140 81 bvB
 Rbe‡ji msL¨v >146,000 >68,000 12,000 >7,447 welq wfwËK †Kvb WvUv cvIqv hvq bvB|
*

3. Bwbw÷wUDU Ae wbDwK¬qvi †gwWwmb I evsjv‡`k GbvUwgK GbvwR© Kwgkb KZ…©K †ivM wbY©‡qi Rb¨ wWGbG
†cÖve e¨envi, evi‡Wg/ BIRDEM KZ…©K RywfbvBj Wvqv‡ewU‡mi ‡R‡bwUK c¨vUvb© wbY©q I XvKv †gwWK¨vj
wWGbG j¨ve‡iUix KZ©©„K d‡ibwmK weÁvb wWGbG cÖhyw³i e¨envi| Ab¨ cÖwZôvbmg~n †hgb, e½eÜz †kL
gywRe †gwW‡Kj wek¦we`¨vj‡q (BSMMU)I knx` †mvn&ivIqv`x© †gwW‡Kj K‡jR (ShSMCH)G wPwKrmv Rxe
cÖhyw³ wel‡h KvR Kivi mvg_©¨ iwnqv‡Q|
evsjv‡`‡ki Jla wk‡í wPwKrmv Rxe cÖhyw³i †ÿ‡Î m‡e©v”P Ae`vb ivwL‡Z cv‡i| G LvZ BwZg‡a¨ c~Y©Zv
AR©b Kwiqv‡Q Ges Jla idZvwb‡Z wek¦ evRv‡i k³ Ae¯’vb m„wó Kwi‡Z cvwiqv‡Q| wKQz wKQz Jla
†Kv¤úvbx BwZg‡a¨B bZzb bZzb wPwKrmv Rxe cÖhyw³ cY¨ Drcv`b ïiæ Kwiqv‡Q| †hgb Bbmywjb, K¨vÝvi
wb‡ivaK Jla, B›Uvi‡dib BZ¨vw`| f¨vKwmb I WvqvMbw÷K wKU&m Drcv`‡bi cÖ‡Póv ïiæ nBqv‡Q|
GB me g~j¨evb AwfÁZv mn‡RB wPwKrmv Rxe cÖhyw³i cÖmv‡ii Kv‡R jvMv‡bv m¤¢e| †`‡ki mKj †gwW‡Kj
K‡jR I mswkøó Ab¨vb¨ cÖwZôv‡b wPwKrmv Rxe cÖhyw³i WvqvMbw÷K I M‡elYv myweav e„w× Kiv GLb mg‡qi `vwe
Ges wPwKrmv Rxe cÖhyw³i †gŠwjK AeKvVv‡gv m¤úªmvib AZxe cÖ‡qvRb| miKv‡ii †emiKvix D‡`¨vM‡K
¯^vMZt Rvbv‡bvi bxwZ Ges miKvix-‡emiKvix Askx`vwiZ¡ msµvšÍ mv¤úªwZK hyMvšÍKvix wm×všÍ GB wel‡q
A_©‰bwZK Dbœq‡b bZzb hy‡Mi m~Pbv Kwi‡e|
wPwKrmv Rxe cÖhyw³ welqK RvZxq MvBW jvBb'(D‡jøL†hvM¨ mycvwik mg~n):
(m~Î t RvZxq Rxe cÖhyw³ †M‡RU: 2005 ,2010, 2013 )|
 wPwKrmv Rxe cÖhyw³i wel‡q h_vh_ ¸iæZ¡ cÖ`v‡bi wbwg‡Ë¡ †gwW‡Kj KvwiKzjvg nvjbvMv` Kiv (aviv -
3.3.2) |
 †`‡ki wPwKrmv welqK cvVvMvi¸‡jv‡Z wPwKrmv Rxe cÖhyw³i wi‡mv©m e„w×KiY (aviv- 3.3.3) |
 wPwKrmv Rxe cÖhyw³ wel‡q ¯œvZ‡KvËi I †UK‡bvjwR÷ †Kvm© Pvjy Kiv ( aviv-3.3.4)|
 Dchy³ I AvMÖnx Rbej wPwýZ K‡i µgvš^‡q †`‡k I we‡`‡k wPwKrmv Rxe cÖhyw³ wel‡q cÖwkÿY cÖ`vb
(aviv- 3.3.5)|
 cÖwZôvwbK mÿgZv e„w× t (aviv- 3.4) |
 gwjwKDjvi †R‡bwUK wW‡UKkb,WvqvMbwmm,KvD‡Ýwjs Ges wUªU‡g›U myweav M‡o ‡Zvjv (3.4.1)|
 wPwKrmv Rxe cÖhyw³i M‡elYv cÖK‡í mnvqZv cÖ`vb (aviv- 3.5.1,) |
 †`k Ges we‡`‡ki `ªæZ AMÖmigvb wPwKrmv Rxe cÖhyw³i Pvwn`v c~iYK‡í †`‡k wek¦gv‡bi wPwKrmv Rxe
cÖhyw³ welqK wkÿv AeKvVv‡gv Ges M‡elYv wfwË _vwK‡e| (aviv- 3.7.4) |
 wPwKrmv Rxe-cÖhyw³ welqK RvZxq MvBW jvBb †hb h_vh_fv‡e ev¯ÍvewqZ nq ¯^v¯’¨ I cwievi cwiKíbv
gš¿Yvjq Zvnv wbwðZ Kwi‡e| (aviv- 3.8) |

4. (http://www.dghs.gov.bd/index.php/en/medical-biotechnology/87-english-root/medical-
biotechnology/499-medical-biotechnology-program-of-hpnsdp-2011-16-of-bangladesh-health-
ministry)
Medical biotechnology program of HPNSDP 2011-16 of Bangladesh Health Ministry-
The Bangladesh government has undertaken a program on medical biotechnology
through its 5-year long Health, Population & Nutrition Sector Development Program
2011-16 (HPNSDP 2011-16) of the Ministry of Health & Family Welfare. This
program is called "Medical Biotechnology (MBT) and is included in the Operational
Plan "Health Information System & e-Health" of DGHS.
Background
The government has taken policy decisions for rapid deployment of medical
biotechnology, to confront country’s future health, nutrition and livelihood
challenges.
The government constituted a National Taskforce on Biotechnology with Honorable
Prime Minister as chair and adopted National Biotechnology Policy and several
sector-specific National Biotechnology Guidelines including National Guidelines on
Medical Biotechnology.
The later has been published as government gazette and spells out MOHFW’s
deliverables in next 25 years. In HPNSDP 2011-16, the medical biotechnology has
been included as a regular program of the Ministry of Health & Family Welfare.
5-year (2011-16) MBT implementation plan:
 Short and medium term
1. Establishment of Center for Medical Biotechnology;
2. Situation analysis and development of medical biotechnology plan;
3. Human resource development through sensitization/orientation
training/workshops, updating medical curriculum with focus on medical
biotechnology, improving medical biotechnology resources in medical libraries,
introducing postgraduate and technologist courses, identifying and training
career group for medical biotechnology gradually, orientation of the core group
members and concerned officials on medical biotechnology;
4. Institutional capacity building through development of lab facilities, clinical
services and epidemiological surveillance for medical biotechnology;

5. 5. Creating R&D environment through supporting related research projects,
opening Department of Medical Biotechnology in the National Institute of
Biotechnology, establishment of a Center of Excellence for medical biotechnology,
and appropriate communication programs with potential entrepreneurs of
medical biotechnology; and
6. Creation of public awareness and regulatory system through conducting
appropriate public awareness programs, and developing and enforcing
standards, codes of practice and regulatory framework for medical
biotechnology.
 Long term
Conditions will be created to attain following long term ( Year 2030+) MBT goals:
1. Medical biotechnology initiatives and infrastructures at globally competitive
level;
2. Medical biotechnology industries, laboratories and services capable to compete
globally and keep pace with global development trends;
3. Production of high quality medical biotechnology products and services for local
market as well as for export to the global market; and
4. A world-class higher education and research base to serve the rapidly growing
medical biotechnology needs both in home and in abroad.